Gilead buys Nimbus’s NASH portfolio

Friday, April 8, 2016 - 16:47 in Health & Medicine

$400 million deal adds ACC inhibitors to Gilead’s liver disease pipeline

Read the whole article on C&EN

Get the latest and most popular science news articles of the week in your Inbox! It's free!